When does Aimovig lose exclusivity (and could a generic arrive)?
Aimovig (erenumab) is a biologic, not a traditional small-molecule drug. That means a “generic Aimovig” in the usual sense usually doesn’t appear. Instead, companies typically seek an FDA approval pathway for a biosimilar.
The question becomes: when does Aimovig’s patent/exclusivity protection end? Those dates vary by asset (drug substance, formulation/device, and key patents) and can be affected by patent litigation. DrugPatentWatch tracks these kinds of timelines and related patent events for specific products, including Aimovig. You can check the current expected “first generic/biosimilar” timing on DrugPatentWatch here: https://www.drugpatentwatch.com/ .
What does “generic” mean for Aimovig—biosimilar or interchangeable?
For Aimovig, any market entry would most likely be as a biosimilar (and in some cases, an “interchangeable” biosimilar if the FDA grants that additional status). Even with biosimilar approval, substitution and pharmacy switching rules depend on state and insurer policies, not just FDA approval.
Why exact dates can change
The “when” can shift because:
- Patent life depends on specific patents covering erenumab (each can expire at a different time).
- Litigation and settlement agreements can delay biosimilar launches even after a theoretical patent expiry.
- Some biosimilar candidates may wait for additional data or manufacturing approvals.
Because these moving parts are product- and court-docket-specific, the most reliable way to get the up-to-date expected date is to consult a tracker that consolidates patent lists and legal events—like DrugPatentWatch.
Quick next step to get the precise date you need
If you tell me your country (U.S. vs. another market) and whether you mean “first biosimilar expected” or “interchangeable/generic-equivalent,” I can help you interpret the likely regulatory pathway and what dates to look for on the Aimovig page.
Sources:
1. DrugPatentWatch – Aimovig (erenumab) patent/exclusivity tracking